文献速递前列腺增生与排尿功能障碍

可能影响女性压力性尿失禁尿道注射治疗效果的患者特征

Patient Characteristics that May Influence the Effect of Urethral Injection Therapy for Female Stress Urinary Incontinence.
PubMed 文献 · J Urol · 2019-06-07

本研究为一项已发表的33中心随机对照试验的事后分析,比较Bulkamid®水凝胶与Contigen®胶原凝胶治疗女性压力性尿失禁,共纳入291例女性(水凝胶191例、胶原100例)。治疗1年后25%治愈、56%改善、18%无效;多因素logistic回归显示年龄≥60岁且每日压力性尿失禁发作<2.5次与治愈相关,该组90%有治疗反应、38%治愈,而<60岁且每日≥2.5次者治愈率为13%。

要点

  • 年龄≥60岁且每日压力性尿失禁发作<2.5次者治疗反应率90%、治愈率38%。
  • 年龄<60岁且每日发作≥2.5次者治愈率为13%。
  • 总体1年治愈25%、改善56%、无效18%。

核心结论

  • 尿道注射治疗对年龄60岁或以上且每日压力性尿失禁发作少于2.5次的女性更有效,该组成功率为90%。

研究设计与样本

  • 本研究为一项已发表的随机、33中心研究的事后分析,比较Bulkamid®水凝胶填充剂与Contigen®胶原凝胶。
  • 初始随机345例女性中291例纳入本研究,其中191例接受水凝胶、100例接受胶原。

主要发现

  • 治疗1年时74例(25%)治愈、164例(56%)改善、53例(18%)无效。
  • 多因素logistic回归分析显示年龄60岁或以上及每日压力性尿失禁发作少于2.5次与治愈相关。
  • 该组90%的女性出现治疗反应、38%治愈,而年龄小于60岁且每日发作2.5次或以上者治愈率为13%。

关键数值与推荐

  • 治愈定义为膀胱日记无压力性尿失禁发作且ICIQ-UI-SF无压力性尿失禁症状。
  • 改善定义为压力性尿失禁发作减少50%或以上。
  • 无效定义为压力性尿失禁发作减少少于50%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Urethral injection therapy is a well-known treatment of female stress urinary incontinence but to our knowledge the optimal group of recipients has not been established. In this study we examined which patient characteristics are associated with success after urethral injection therapy. MATERIALS AND METHODS: This study is a post hoc analysis of a previously published, randomized, 33-center study of the hydrogel bulking agent Bulkamid® vs the collagen gel Contigen®. Regardless of the treatment women were considered cured if there were no stress incontinence episodes in the bladder diary and no stress incontinence symptoms on the ICIQ-UI-SF (International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form), improved if there was a 50% or greater reduction in stress incontinence episodes and no effect if there was less than a 50% reduction in stress incontinence episodes 1 year after treatment. RESULTS: Of the 345 women who were initially randomized 291 were included in this study. A total of 191 women received hydrogel and 100 received collagen. At 1 year 74 women (25%) were cured, 164 (56%) were improved and 53 (18%) showed no effect. On multivariate logistic regression analysis age 60 years or greater and fewer than 2.5 daily stress incontinence episodes were associated with cure. In this group 90% of women experienced a treatment effect and 38% were cured compared with a 13% cure rate in those younger than 60 years with 2.5 or more daily stress incontinence episodes. CONCLUSIONS: Urethral injection therapy was more effective to treat stress urinary incontinence in women 60 years old or older with fewer than 2.5 daily stress incontinence episodes. It had a 90% success rate in these women.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Elmelund M, Sokol ER, Karram MM, et al. Patient Characteristics that May Influence the Effect of Urethral Injection Therapy for Female Stress Urinary Incontinence. J Urol. 2019. PMID: 30810462. doi:10.1097/JU.0000000000000176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。